Latest Conference Articles

Pharmacy Times® interviewed Charles Nakar, MD and Amy Shapiro, MD, of the Indiana Hemophilia & Thrombosis Center, on how airway obstruction and respiratory distress can impact pediatric patients versus adult patients.

Pharmacy Times® interviewed Charles Nakar, MD and Amy Shapiro, MD, of the Indiana Hemophilia & Thrombosis Center, on what the treatment options are for patients with congenital plasminogen deficiency with airway obstruction and respiratory distress.

Pharmacy Times® interviewed Christopher Moxham of Fulcrum Therapeutics, on what FTX-6058 is, how it was developed, and what it is able to treat.

Pharmacy Times® interviewed Christopher Moxham of Fulcrum Therapeutics, on how maintaining expression of the anti-sickling gamma ortholog could be beneficial for children and adults with sickle cell disease, and why this is important to investigate.

Pharmacy Times® interviewed Charles Nakar, MD and Amy Shapiro, MD, of the Indiana Hemophilia & Thrombosis Center, on the common manifestations of congenital plasminogen deficiency, and whether it is life threatening for patients.

Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on the common treatments for patients with polycythemia vera.

Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on the survival estimates for patients with polycythemia vera in the past and the mortality rates among these patients.

Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on what polycythemia vera (PV) is and why it was important to understand mortality and causes of death among patients with PV.

Pharmacy Times® interviewed Christopher Moxham of Fulcrum Therapeutics, on what sickle cell disease and beta-thalassemias are caused by, and how hemoglobin gamma can prevent or reduce disease-related pathophysiology in these disorders.

Five oral presentations will include data on the use of gilteritinib, either as monotherapy or in combination, across the spectrum of patients with acute myeloid leukemia with a positive FLT3 mutation.

Results of a recent study confirmed that patients already taking angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) should not discontinue taking them due to COVID-19 infection.

For patients with COVID-19, the combination of the disease and preexisting atrial arrhythmias may create a pathologic synergy that significantly increases the risk for major adverse cardiac events and death.

The researchers examined the health records of more than 1100 adults, who had an average age of 45 years, were 52% female, and who are participants in the ongoing Childhood Determinants of Adult Health study.

Green spaces were also associated with an improvement in air quality.

Centhaquine was found to improve survival in those with hypovolemic shock.

A majority of young adults with cardiovascular disease are not receiving the annual influenza vaccine despite their heightened risk of secondary infections.

Researchers analyzed the survey responses of more than 1400 current users of e-cigarette and related products from 18 to 64 years of age, evenly divided among male and female, who took part in a national online survey in 2016.

Cannabis use is becoming much more prevalent in the United States, as several more states have recently legalized it for recreational or medicinal use.

The COVID-19 pandemic has forced many cardiovascular rehabilitation programs to go virtual.

At ESMO 2020, researchers discussed some long-awaited data regarding postoperative radiotherapy used in patients with non-small cell lung cancer following complete resection and after (neo) adjuvant chemotherapy.

Among patients with cervical cancer, there was no significant difference found between the risk of recurrence, local recurrence, or death among individuals who either completed or abandoned a radical uterine procedure following the intraoperative detection of a positive pelvic lymph node.

Study shows that upon hospital admission for cancer, many patients already have a high prevalence of malnutrition per Global Leadership Initiative on Malnutrition criteria.

The results from a cohort of patients with rare sarcomas in the phase 2 study, presented by professor Jean-Yves Blay, MD, investigated the efficacy and safety of single agent pembrolizumab in rare cancers.

A new study showed that nivolumab was effective in patients with pathogenic exonuclease domain POLE mutated mismatch repair.

The effects of pralsentinib were especially pronounced in treatment-naïve patients with medullary thyroid cancer.

The predictive value provided by T effector and angiogenesis signatures were found to be augmented by Kidney Immune Classification of tumor microenvironments.

Although immune checkpoint inhibitors are not yet approved for first-line therapy in these populations, the new research could lead to a new standard of care.

Adding atezolizumab (Tecentriq) to bevacizumab (Avastin) and chemotherapy failed to significantly improve progression-free survival in patients with newly diagnosed stage III/IV ovarian cancer.

The COVID-19 pandemic will be felt in the oncology space long after the pandemic is over, study shows.

The CheckMate 9ER trial took 2 drugs used as monotherapies in the second line of therapy, nivolumab and cabozantinib, and combined them for use as a first-line treatment against standard of care, sunitinib.